Overview Dividends

(UHS) Universal Health - Ratings and Ratios

Exchange: NYSE • Country: United States • Currency: USD • Type: Common Stock • ISIN: US9139031002

Hospitals, Outpatient Centers, Behavioral Health, Surgery, Insurance

UHS EPS (Earnings per Share)

EPS Growth (3Y CAGR): 25.90%
EPS Trend (3Y Correlation): 93.0%

UHS Revenue

Revenue Growth (3Y CAGR): 10.14%
Revenue Trend (3Y Correlation): 98.8%

Risk via 10d forecast
Volatility	32.5%
Value at Risk 5%th	47.5%

Reward
Sharpe Ratio	0.41
Alpha	-13.39

Character
Hurst Exponent	0.656
Beta	1.305

Drawdowns 3y
Max DD	35.64%
Mean DD	12.48%

Description: UHS Universal Health October 30, 2025

Universal Health Services, Inc. (NYSE: UHS) operates a nationwide network of acute-care hospitals and behavioral-health facilities through two segments: Acute Care Hospital Services and Behavioral Health Care Services. Its service portfolio spans general and specialty surgery, obstetrics, emergency care, radiology, oncology, pediatric and coronary care, as well as comprehensive behavioral-health programs, supplemented by ancillary services such as pharmacy, central purchasing, and physician recruitment.

Key financial indicators from the most recent fiscal year show revenue of roughly $9.4 billion and an adjusted operating margin near 7 %, while average hospital occupancy hovers around 78 %, reflecting modest capacity utilization in a market still adjusting to post-pandemic demand dynamics.

Sector-level drivers that materially affect UHS include the aging U.S. population, which fuels higher inpatient and chronic-care utilization, and ongoing Medicare/Medicaid reimbursement reforms that pressure pricing power. Additionally, the industry’s shift toward outpatient and tele-health services creates both growth opportunities and competitive pressures for traditional hospital operators.

For deeper quantitative analysis, the ValueRay platform offers granular cash-flow and valuation metrics that can help assess UHS’s upside.

UHS Stock Overview

Market Cap in USD	14,045m
Sub-Industry	Health Care Facilities
IPO / Inception	1990-03-26
Return 12m vs S&P 500	-2.68%
Analyst Rating	3.79 of 5

UHS Dividends

Dividend Yield	0.35%
Yield on Cost 5y	0.65%
Yield CAGR 5y	41.42%
Payout Consistency	56.8%
Payout Ratio	3.9%

UHS Growth Ratios

CAGR	23.25%
CAGR/Max DD Calmar Ratio	0.65
CAGR/Mean DD Pain Ratio	1.86
Current Volume	573.2k
Average Volume	548.6k

Piotroski VR‑10 (Strict, 0-10) 9.0

Net Income (1.38b TTM) > 0 and > 6% of Revenue (6% = 1.02b TTM)

FCFTA 0.09 (>2.0%) and ΔFCFTA 2.28pp (YES ≥ +1.0pp, WARN ≥ +0.5pp)

NWC/Revenue 0.58% (prev 5.13%; Δ -4.55pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp)

CFO/TA 0.19 (>3.0%) and CFO 2.86b > Net Income 1.38b (YES >=105%, WARN >=100%)

Net Debt (5.00b) to EBITDA (2.59b) ratio: 1.93 <= 3.0 (WARN <= 3.5)

Current Ratio 1.03 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active)

Outstanding Shares last Quarter (65.0m) change vs 12m ago -4.58% (target <= -2.0% for YES)

Gross Margin 90.34% (prev 89.78%; Δ 0.56pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0)

Asset Turnover 114.4% (prev 107.4%; Δ 7.02pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0)

Interest Coverage Ratio 12.96 (EBITDA TTM 2.59b / Interest Expense TTM 153.5m) >= 6 (WARN >= 3)

Altman Z'' 3.44

(A) 0.01 = (Total Current Assets 3.26b - Total Current Liabilities 3.16b) / Total Assets 15.34b

(B) 0.48 = Retained Earnings (Balance) 7.37b / Total Assets 15.34b

(D) 0.89 = Book Value of Equity 7.17b / Total Liabilities 8.05b

Total Rating: 3.44 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D)

ValueRay F-Score (Strict, 0-100) 82.26

1. Piotroski 9.0pt = 4.0

2. FCF Yield 7.21% = 3.60

3. FCF Margin 8.08% = 2.02

4. Debt/Equity 0.71 = 2.26

5. Debt/Ebitda 1.93 = 0.14

6. ROIC - WACC (= 5.22)% = 6.52

7. RoE 19.85% = 1.65

8. Rev. Trend 98.82% = 7.41

9. EPS Trend 93.02% = 4.65

What is the price of UHS shares?

As of November 11, 2025, the stock is trading at USD 229.23 with a total of 573,200 shares traded.
Over the past week, the price has changed by +3.86%, over one month by +13.71%, over three months by +33.68% and over the past year by +10.38%.

Is Universal Health a good stock to buy?

Yes, based on ValueRay´s Fundamental Analyses, Universal Health (NYSE:UHS) is currently (November 2025) a good stock to buy. It has a ValueRay Fundamental Rating of 82.26 and therefor a positive outlook according to the companies health.
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of UHS is around 233.95 USD . This means that UHS is currently overvalued and has a potential downside of 2.06%.

Is UHS a buy, sell or hold?

Universal Health has received a consensus analysts rating of 3.79. Therefor, it is recommend to hold UHS.

Strong Buy: 7
Buy: 1
Hold: 11
Sell: 0
Strong Sell: 0

What are the forecasts/targets for the UHS price?

Issuer	Target	Up/Down from current
Wallstreet Target Price	243.9	6.4%
Analysts Target Price	243.9	6.4%
ValueRay Target Price	259.9	13.4%

UHS Fundamental Data Overview November 05, 2025

Market Cap USD = 14.05b (14.05b USD * 1.0 USD.USD)
P/E Trailing = 10.5045
P/E Forward = 9.2081
P/S = 0.8265
P/B = 1.8606
P/EG = 1.87
Beta = 1.305
Revenue TTM = 16.99b USD
EBIT TTM = 1.99b USD
EBITDA TTM = 2.59b USD
Long Term Debt = 4.46b USD (from longTermDebt, last fiscal year)
Short Term Debt = 813.5m USD (from shortTermDebt, last quarter)
Debt = 5.11b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 5.00b USD (from netDebt column, last quarter)
Enterprise Value = 19.04b USD (14.05b + Debt 5.11b - CCE 112.9m)
Interest Coverage Ratio = 12.96 (Ebit TTM 1.99b / Interest Expense TTM 153.5m)
FCF Yield = 7.21% (FCF TTM 1.37b / Enterprise Value 19.04b)
FCF Margin = 8.08% (FCF TTM 1.37b / Revenue TTM 16.99b)
Net Margin = 8.09% (Net Income TTM 1.38b / Revenue TTM 16.99b)
Gross Margin = 90.34% ((Revenue TTM 16.99b - Cost of Revenue TTM 1.64b) / Revenue TTM)
Gross Margin QoQ = 90.78% (prev 90.22%)
Tobins Q-Ratio = 1.24 (Enterprise Value 19.04b / Total Assets 15.34b)
Interest Expense / Debt = 0.75% (Interest Expense 38.4m / Debt 5.11b)
Taxrate = 23.70% (117.8m / 496.9m)
NOPAT = 1.52b (EBIT 1.99b * (1 - 23.70%))
Current Ratio = 1.03 (Total Current Assets 3.26b / Total Current Liabilities 3.16b)
Debt / Equity = 0.71 (Debt 5.11b / totalStockholderEquity, last quarter 7.23b)
Debt / EBITDA = 1.93 (Net Debt 5.00b / EBITDA 2.59b)
Debt / FCF = 3.64 (Net Debt 5.00b / FCF TTM 1.37b)
Total Stockholder Equity = 6.93b (last 4 quarters mean from totalStockholderEquity)
RoA = 8.96% (Net Income 1.38b / Total Assets 15.34b)
RoE = 19.85% (Net Income TTM 1.38b / Total Stockholder Equity 6.93b)
RoCE = 17.46% (EBIT 1.99b / Capital Employed (Equity 6.93b + L.T.Debt 4.46b))
RoIC = 13.30% (NOPAT 1.52b / Invested Capital 11.41b)
WACC = 8.09% (E(14.05b)/V(19.16b) * Re(10.82%) + D(5.11b)/V(19.16b) * Rd(0.75%) * (1-Tc(0.24)))
Discount Rate = 10.82% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: -100.0 | Cagr: -2.63%
[DCF Debug] Terminal Value 72.95% ; FCFE base≈1.21b ; Y1≈1.49b ; Y5≈2.54b
Fair Price DCF = 486.3 (DCF Value 27.42b / Shares Outstanding 56.4m; 5y FCF grow 25.0% → 3.0% )
EPS Correlation: 93.02 | EPS CAGR: 25.90% | SUE: 3.36 | # QB: 4
Revenue Correlation: 98.82 | Revenue CAGR: 10.14% | SUE: 3.02 | # QB: 2

Additional Sources for UHS Stock

News: Wall Street Journal | Benzinga | Yahoo Finance
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle